Cumulative survival rates for Hodgkin and non-Hodgkin resistant/relapsed lymphoma patients treated with bendamustine, etoposide, cytarabine and melphalan followed by autologous stem cell rescue. (A) Progression-free and (B) overall survival of all patients.